This site is intended for healthcare professionals only

DiabetesontheNet Logo
×


Diabetes Digest

Issue:

Early View

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

Canagliflozin effective in primary and secondary prevention of CV outcomes

Cardiovascular – December 2019 digest

CREDENCE trial finds canagliflozin reduces cardiovascular and renal outcomes in people with type 2 diabetes and chronic kidney disease

Mahaffey KW, Jardine MJ, Bompoint S et al (2019) Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: Results from the randomized CREDENCE trial. Circulation 140: 739–50

  • Individuals with type 2 diabetes and chronic kidney disease have an increased risk of cardiovascular disease. SGLT-2 inhibitors reduce the risk of kidney failure in these patients but their effects on different cardiovascular outcomes and primary prevention were unclear.
  • The Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE) study demonstrated that the addition of canagliflozin to standard care prevented cardiovascular and renal outcomes. In this paper, investigators analysed individual cardiovascular outcomes for participants with and without cardiovascular disease (CVD).
  • Of the 4,401 CREDENCE participants, 2,181 had no history of CVD at enrolment. When compared to the 2,220 secondary prevention participants, on average individuals without CVD had a 1-year shorter history of diabetes and were 4 years younger. A higher proportion of primary prevention participants were female.
  • Treatment with canagliflozin resulted in consistent and significant reductions in the risk of major cardiovascular events in both the primary and secondary prevention groups. When split into individual components, the reductions in cardiovascular death, non-fatal stroke, non-fatal myocardial infarction and hospitalisation for heart failure were similar in both groups.
  • The risk of renal outcomes (end-stage kidney disease, doubling of serum creatine, or renal or cardiovascular death) was similarly reduced in the primary and secondary prevention groups.
  • Investigators concluded that in patients with type 2 diabetes and chronic kidney disease, canagliflozin results in robust and consistent reductions in cardiovascular and renal outcomes when used for primary and secondary prevention. 

Click here to access the article in full

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.